Code Therapeutics News Today

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 ...

HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock. TransCode Therapeutics Stock Performance RNAZ stock opened at $1.15 on Thursday. The stock’s 50 day moving average price is […]

Cogent Biosciences (NASDAQ:COGT – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Analyst Ratings This is a breakdown of […]

See which leaders are on the move across the pharma, biotech and medical marketing industries.

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 18,600 shares, a decline of 53.5% from the March 31st total of 40,000 shares. Based on an average daily volume of 588,800 shares, […]

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. TransCode Therapeutics Stock Performance RNAZ stock opened at $0.50 on Tuesday. TransCode Therapeutics has a 52 week low of $0.47 and a 52 […]

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – HC Wainwright upped their FY2024 EPS estimates for TransCode Therapeutics in a research report issued on Wednesday, April 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.14) per share for the year, up from their prior estimate of ($25.20). HC […]

BOSTON, April 03, 2024 -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and...

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. TransCode Therapeutics Stock Performance Shares of RNAZ traded down $0.01 during trading hours on Wednesday, reaching $0.67. 138,372 shares of the company traded hands, compared to its […]